Cogent Biosciences, Inc. (COGT): who owns it and who trades it
As of Nov 16, 2026, COGT insiders reported 8 open-market sales worth $384M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fairmount Funds Management LLC (Director), with $370M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Cogent Biosciences
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns COGT
321 funds and institutions reported COGT shares worth $7.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 25.68M | 15.03% | $994M | +11% |
| BlackRock, Inc. | 17.35M | 10.16% | $672M | +8% |
| Vanguard Portfolio Management LLC | 8.07M | 4.72% | $312M | +10% |
| Vanguard Capital Management LLC | 7.41M | 4.34% | $287M | +8% |
| State Street Corp | 6.96M | 4.08% | $270M | +23% |
| Jupiter Topco LLC | 6.62M | 3.88% | $256M | – |
| Fairmount Funds Management LLC | 5.50M | 3.22% | $213M | No change |
| California State Teachers Retirement System | 5.48M | 3.21% | $142M | – |
| Deerfield Management Company, L.P. | 5.01M | 2.93% | $194M | -45% |
| TCG Crossover Management, LLC | 4.85M | 2.84% | $188M | -2% |
| T. Rowe Price Associates | 4.65M | 2.72% | $180M | +45% |
| Geode Capital Management, LLC | 4.51M | 2.64% | $175M | +22% |
| Wellington Management Group LLP | 4.34M | 2.54% | $168M | +21% |
| Kynam Capital Management, LP | 3.67M | 2.15% | $142M | -9% |
| Lord, Abbett & Co. LLC | 3.43M | 2.01% | $133M | +8% |
| Polar Capital Holdings Plc | 3.23M | 1.89% | $125M | – |
| Commodore Capital LP | 3.05M | 1.79% | $118M | +6% |
| Assenagon Asset Management S.A. | 2.88M | 1.69% | $112M | +875% |
| Invesco Ltd. | 2.61M | 1.53% | $101M | +7% |
| Woodline Partners LP | 2.60M | 1.52% | $101M | +72% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, COGT insiders reported $0 of open-market purchases and $384M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Arlene Morris | Director | Sale | 3,161 | $37.54 | $119K | Form 4 |
| Aug 27, 2026 | Arlene Morris | Director | Sale | 42,349 | $37.09 | $1.6M | Form 4 |
| Mar 31, 2026 | Fairmount Funds Management LLC | Director | Sale | 7.00M | $34.66 | $243M | Form 4 |
| Jan 22, 2026 | Fairmount Funds Management LLC | Director | Sale | 3.50M | $36.40 | $127M | Form 4 |
| Dec 26, 2025 | Evan Kearns | Chief Legal Officer | Sale | 65,000 | $38.70 | $2.5M | Form 4 |
| Dec 26, 2025 | John L. Green | CFO | Sale | 77,000 | $38.68 | $3M | Form 4 |
| Dec 26, 2025 | Jessica Sachs | Chief Medical Officer | Sale | 82,642 | $38.70 | $3.2M | Form 4 |
| Dec 26, 2025 | John Edward Robinson | Chief Scientific Officer | Sale | 90,000 | $38.74 | $3.5M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Fairmount Funds Management LLC | Director | – | $370M | Mar 31, 2026 |
| John Edward Robinson | Chief Scientific Officer | – | $3.5M | Dec 26, 2025 |
| Jessica Sachs | Chief Medical Officer | – | $3.2M | Dec 26, 2025 |
| John L. Green | Chief Financial Officer | – | $3M | Dec 26, 2025 |
| Evan Kearns | Chief Legal Officer | – | $2.5M | Dec 26, 2025 |
| Arlene Morris | Director | – | $1.7M | Aug 27, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
COGT short interest
High short interest. 10.0% of COGT shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 56%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17.42M COGT shares were sold short, 10.0% of the shares outstanding, down 11.4% from the report before. At the average daily volume of 2.01M shares, buying them all back would take about 8.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17.42M | 10.04% | -11% | 2.01M | 8.7 |
| Oct 15, 2026 | 19.66M | 11.33% | +1% | 2.20M | 8.9 |
| Sep 30, 2026 | 19.46M | 11.22% | +7% | 2.41M | 8.1 |
| Sep 15, 2026 | 18.13M | 10.45% | -3% | 1.53M | 11.8 |
| Aug 31, 2026 | 18.75M | 10.80% | +2% | 1.55M | 12.1 |
| Aug 14, 2026 | 18.41M | 10.61% | +3% | 2.06M | 8.9 |
| Jul 31, 2026 | 17.89M | 10.47% | +8% | 1.70M | 10.5 |
| Jul 15, 2026 | 16.56M | 9.69% | +1% | 2.47M | 6.7 |
| Jun 30, 2026 | 16.35M | 9.57% | +22% | 4.22M | 3.9 |
| Jun 15, 2026 | 13.45M | 7.87% | +17% | 2.31M | 5.8 |
| May 29, 2026 | 11.52M | 6.74% | +3% | 2.37M | 4.9 |
| May 15, 2026 | 11.16M | 6.53% | -5% | 1.49M | 7.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Cogent Biosciences company events
Cogent Biosciences filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 2, 2026AgreementCogent Biosciences, Inc. entered into a Commercial Supply Agreement with Hovione FarmaCiencia S.A. to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets. Filing
- Aug 10, 2026AnnouncementAs previously disclosed, on May 6, 2022, Cogent Biosciences, Inc. entered into a Sales Agreement with Guggenheim Securities, LLC, as amended by that certain Amendment No. 1 to Sales Agreement, dated November 7, 2025 (as amended, the “Sales Agreement”), pursuant to which the Company may offer and… Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Feb 17, 2026ResultsReleased financial results. Filing
- Dec 8, 2025AnnouncementOn December 6, 2025 and December 8, 2025, Cogent Biosciences, Inc. presented the full results from its SUMMIT clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis and announced positive top-line results from its APEX clinical trial of bezuclastinib in patients with… Filing
- Nov 18, 2025AgreementCogent Biosciences, Inc. completed its previously-announced public offering of $230 million of its 1.625% Convertible Senior Notes due 2031, including the exercise in full of the underwriters’ over-allotment option to purchase up to an additional $30.0 million principal amount of the Notes. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cogent Biosciences financials
Famous investors that hold COGT
6 of the 50 well-known investors we track reported holding COGT in their latest 13F filing. The largest position is Ken Griffin's, worth $31.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 990,010 | $31.7M | 0.0% | +17% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 790,494 | $25.3M | 0.0% | +6% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 708,668 | $22.7M | 0.0% | -29% |
| Israel Englander · Millennium Management | Q3 2026 | 324,672 | $10.4M | 0.0% | -64% |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 221,112 | $7.1M | 0.2% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 152,498 | $4.9M | 0.0% | -18% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Cogent Biosciences, Inc. (COGT) stock
Who owns the most COGT stock?
The largest reported owner of Cogent Biosciences, Inc. (COGT) is FMR LLC (Fidelity), with 15.0% of the company. In total, 321 funds and institutions reported holding COGT at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are COGT insiders buying or selling?
In the last 12 months, COGT insiders reported no open-market purchases and 8 sales worth $384M. The latest trade was on Aug 27, 2026. See every trade.
What is the short interest in COGT?
As of Oct 30, 2026, 17.42M COGT shares were sold short, 10.0% of the shares outstanding, down 11.4% from the report before. At the average daily volume of 2.01M shares, buying them all back would take about 8.7 trading days (days to cover). See the history.
Which famous investors hold COGT?
6 of the 50 well-known investors we track reported COGT in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $31.7M. See all holders.
Executive pay
Cogent Biosciences's chief executive was paid a total of $27.8M for the year ended Dec 31, 2025, up 465% from $4.9M the year before. In the last 12 months, Cogent Biosciences's executives and directors bought no stock on the open market and sold $13.9M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.